Synthesis and Activity Study of Gefitinib Derivatives Inducing Mitochondrial Apoptosis in Hela Cells
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.70035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Yue Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Zhoukou Center Hospital, Zhoukou, Henan, China. Hauptthemen laut MEDLINE: Apoptosis, Mitochondria, Gefitinib, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Henan Province Medical Science and Technology Research Project.
Abstract (Originalsprache)
Cervical cancer is the fourth most common cancer among women globally. Its development is closely linked to accelerated cell cycle progression and the inhibition of apoptosis in cervical cancer tissues. Gefitinib has demonstrated efficacy in inhibiting cervical cancer cells, and the 1,2,3‐triazole structure is widely recognized for its role in inducing mitochondrial apoptosis in tumor cells. In this study, we employed click chemistry to modify the structure of gefitinib, leading to the synthesis of 16 derivatives containing the 1,2,3‐triazole moiety. These compounds were evaluated for their in vitro activity against Hela cells. Among them, compound 3p exhibited the most promising anticancer activity, with an IC 50 value of 4.09 ± 0.54 μM. Compound 3p significantly inhibited Hela cell colony formation in a dose‐dependent manner, accompanied by noticeable morphological changes. Further investigations revealed that 3p induced apoptosis and caused G2/M phase cell cycle arrest in Hela cells. Western blot analysis showed that 3p increased the Bax/Bcl‐2 ratio and elevated the levels of cleaved caspase‐3 and PARP1, indicating that apoptosis was mediated through the mitochondrial pathway. Additionally, 3p inhibited indoleamine 2,3‐dioxygenase 1 (IDO1) enzymatic activity, and molecular docking studies revealed a strong interaction between 3p and the IDO1 active site, suggesting that IDO1 may be a potential target. In conclusion, compound 3p shows promise as a potential therapeutic agent for cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhoukou Center Hospital, Zhoukou, Henan, China.
- The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, China.
- College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
- Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.
- Henan Wanliu Biotechnology Co., LTD., Luoyang, China.
Förderung
- Henan Province Medical Science and Technology Research Project
Zitieren
APA
Li, Y., Hou, X., Liu, S., Chen, Z., Wu, Q., He, B., Guo, J., Wang, L., Liu, C., & Mao, L. F. (2024). Synthesis and Activity Study of Gefitinib Derivatives Inducing Mitochondrial Apoptosis in Hela Cells. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70035
Vancouver
Li Y, Hou X, Liu S, Chen Z, Wu Q, He B, et al. Synthesis and Activity Study of Gefitinib Derivatives Inducing Mitochondrial Apoptosis in Hela Cells. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70035
BibTeX
@article{Li2024,
author = {Li, Yue and Hou, Xixi and Liu, Shujian and Chen, Zihao and Wu, Qiong and He, Baoyu and Guo, Jingjing and Wang, Lan and Liu, Caihong and Mao, Long-Fei},
title = {Synthesis and Activity Study of Gefitinib Derivatives Inducing Mitochondrial Apoptosis in Hela Cells},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.70035}
}
EUVIMED